This company has been acquired
Alimera Sciences (ALIM) Stock Overview
A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ALIM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alimera Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.54 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$2.61 |
| Beta | 1.25 |
| 1 Month Change | -0.89% |
| 3 Month Change | 81.64% |
| 1 Year Change | 78.14% |
| 3 Year Change | 18.12% |
| 5 Year Change | -34.08% |
| Change since IPO | -96.64% |
Recent News & Updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18
Recent updates
Alimera Sciences: Deal Closing After All, CVR Still Attractive
Sep 11Alimera Sciences: Cheap CVR Optionality
Jul 16Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)
Jun 18Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story
Feb 15Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?
Dec 30Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)
Oct 13Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Sep 13Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data
Oct 06Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland
Sep 20Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection
Aug 09Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection
Jul 22Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation
Jul 08Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?
Mar 24Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?
Nov 06Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem
Aug 24Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares
Feb 11Shareholder Returns
| ALIM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.2% | 2.1% | -0.9% |
| 1Y | 78.1% | 3.8% | 20.1% |
Return vs Industry: ALIM exceeded the US Pharmaceuticals industry which returned 19.2% over the past year.
Return vs Market: ALIM exceeded the US Market which returned 25.3% over the past year.
Price Volatility
| ALIM volatility | |
|---|---|
| ALIM Average Weekly Movement | 22.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALIM's share price has been volatile over the past 3 months.
Volatility Over Time: ALIM's weekly volatility has increased from 13% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 157 | Rick Eiswirth | alimerasciences.com |
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Alimera Sciences, Inc. Fundamentals Summary
| ALIM fundamental statistics | |
|---|---|
| Market cap | US$301.29m |
| Earnings (TTM) | -US$15.27m |
| Revenue (TTM) | US$99.68m |
Is ALIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIM income statement (TTM) | |
|---|---|
| Revenue | US$99.68m |
| Cost of Revenue | US$13.57m |
| Gross Profit | US$86.11m |
| Other Expenses | US$101.39m |
| Earnings | -US$15.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 86.39% |
| Net Profit Margin | -15.32% |
| Debt/Equity Ratio | 179.8% |
How did ALIM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/18 04:30 |
| End of Day Share Price | 2024/09/13 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alimera Sciences, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Caroline Corner | Cantor Fitzgerald & Co. |